Elisa Petris
Director/Board Member at Quell Therapeutics Ltd.
Profile
Elisa is a Lead Partner of Syncona Investment Management Ltd.
She is a Director on the Board of Quell Therapeutics, Beacon Therapeutics and Forcefield Therapeutics and was previously on the Board of former portfolio companies Blue Earth Diagnostics and Neogene, and of current portfolio company Achilles Therapeutics.
She was closely involved in the foundation of Quell, Blue Earth, Achilles and Beacon including their operational and strategic set-up.
Previously, she was a Senior Associate at Michel Dyens & Co. working on transactions covering the healthcare space, and a member of the Life Science team at L.E.K.
Consulting based in London.
While at L.E.K.
she worked on projects for biotech, pharma and private equity clients.
Elisa has a PhD in Molecular Biology from Imperial College and an MBA from London Business School.
Elisa Petris active positions
Companies | Position | Start |
---|---|---|
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 2012-12-31 |
Blue Earth Diagnostics Ltd.
Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Director/Board Member | - |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Director/Board Member | 2019-03-18 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 2016-04-30 |
Former positions of Elisa Petris
Companies | Position | End |
---|---|---|
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Director/Board Member | - |
Training of Elisa Petris
Imperial College London | Doctorate Degree |
London Business School | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
Health Technology |
Private companies | 4 |
---|---|
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
Blue Earth Diagnostics Ltd.
Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Health Services |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Elisa Petris